Evidence map›Paper›PMID 33299667›Full record

ArticleNeurology. Clinical practice2020

Cryptogenic stroke: Contemporary trends, treatments, and outcomes in the United States.

Shyam Prabhakaran, Steven R Messé, Dawn Kleindorfer, Eric E Smith, Gregg C Fonarow, Haolin Xu, Xin Zhao, Barbara Lytle, Joaquin Cigarroa, Lee H Schwamm

Open access · greenAbstract read
In one paragraph

Article in Neurology. Clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Shyam PrabhakaranUniversity of Chicago (SP), Pritzker School of Medicine; University of Pennsylvania (SRM); University of Cincinnati (DK); Hotchkiss Brain Institute (EES), University of Calgary, Calgary, Alberta, Canada; Ahmanson Cardiomyopathy Center (GCF), UCLA, Los Angeles, CA; Duke Clinical Research Institute (HX, XZ, BL), Durham, NC; Knight Cardiovascular Institute (JC), Oregon Health and Sciences University; and Department of Neurology (LHS), Massachusetts General Hospital.
Steven R MesséUniversity of Chicago (SP), Pritzker School of Medicine; University of Pennsylvania (SRM); University of Cincinnati (DK); Hotchkiss Brain Institute (EES), University of Calgary, Calgary, Alberta, Canada; Ahmanson Cardiomyopathy Center (GCF), UCLA, Los Angeles, CA; Duke Clinical Research Institute (HX, XZ, BL), Durham, NC; Knight Cardiovascular Institute (JC), Oregon Health and Sciences University; and Department of Neurology (LHS), Massachusetts General Hospital.
Dawn KleindorferUniversity of Chicago (SP), Pritzker School of Medicine; University of Pennsylvania (SRM); University of Cincinnati (DK); Hotchkiss Brain Institute (EES), University of Calgary, Calgary, Alberta, Canada; Ahmanson Cardiomyopathy Center (GCF), UCLA, Los Angeles, CA; Duke Clinical Research Institute (HX, XZ, BL), Durham, NC; Knight Cardiovascular Institute (JC), Oregon Health and Sciences University; and Department of Neurology (LHS), Massachusetts General Hospital.
Eric E SmithUniversity of Chicago (SP), Pritzker School of Medicine; University of Pennsylvania (SRM); University of Cincinnati (DK); Hotchkiss Brain Institute (EES), University of Calgary, Calgary, Alberta, Canada; Ahmanson Cardiomyopathy Center (GCF), UCLA, Los Angeles, CA; Duke Clinical Research Institute (HX, XZ, BL), Durham, NC; Knight Cardiovascular Institute (JC), Oregon Health and Sciences University; and Department of Neurology (LHS), Massachusetts General Hospital.
Gregg C FonarowUniversity of Chicago (SP), Pritzker School of Medicine; University of Pennsylvania (SRM); University of Cincinnati (DK); Hotchkiss Brain Institute (EES), University of Calgary, Calgary, Alberta, Canada; Ahmanson Cardiomyopathy Center (GCF), UCLA, Los Angeles, CA; Duke Clinical Research Institute (HX, XZ, BL), Durham, NC; Knight Cardiovascular Institute (JC), Oregon Health and Sciences University; and Department of Neurology (LHS), Massachusetts General Hospital.
Haolin XuUniversity of Chicago (SP), Pritzker School of Medicine; University of Pennsylvania (SRM); University of Cincinnati (DK); Hotchkiss Brain Institute (EES), University of Calgary, Calgary, Alberta, Canada; Ahmanson Cardiomyopathy Center (GCF), UCLA, Los Angeles, CA; Duke Clinical Research Institute (HX, XZ, BL), Durham, NC; Knight Cardiovascular Institute (JC), Oregon Health and Sciences University; and Department of Neurology (LHS), Massachusetts General Hospital.
Xin ZhaoUniversity of Chicago (SP), Pritzker School of Medicine; University of Pennsylvania (SRM); University of Cincinnati (DK); Hotchkiss Brain Institute (EES), University of Calgary, Calgary, Alberta, Canada; Ahmanson Cardiomyopathy Center (GCF), UCLA, Los Angeles, CA; Duke Clinical Research Institute (HX, XZ, BL), Durham, NC; Knight Cardiovascular Institute (JC), Oregon Health and Sciences University; and Department of Neurology (LHS), Massachusetts General Hospital.
Barbara LytleUniversity of Chicago (SP), Pritzker School of Medicine; University of Pennsylvania (SRM); University of Cincinnati (DK); Hotchkiss Brain Institute (EES), University of Calgary, Calgary, Alberta, Canada; Ahmanson Cardiomyopathy Center (GCF), UCLA, Los Angeles, CA; Duke Clinical Research Institute (HX, XZ, BL), Durham, NC; Knight Cardiovascular Institute (JC), Oregon Health and Sciences University; and Department of Neurology (LHS), Massachusetts General Hospital.
Joaquin CigarroaUniversity of Chicago (SP), Pritzker School of Medicine; University of Pennsylvania (SRM); University of Cincinnati (DK); Hotchkiss Brain Institute (EES), University of Calgary, Calgary, Alberta, Canada; Ahmanson Cardiomyopathy Center (GCF), UCLA, Los Angeles, CA; Duke Clinical Research Institute (HX, XZ, BL), Durham, NC; Knight Cardiovascular Institute (JC), Oregon Health and Sciences University; and Department of Neurology (LHS), Massachusetts General Hospital.
Lee H SchwammUniversity of Chicago (SP), Pritzker School of Medicine; University of Pennsylvania (SRM); University of Cincinnati (DK); Hotchkiss Brain Institute (EES), University of Calgary, Calgary, Alberta, Canada; Ahmanson Cardiomyopathy Center (GCF), UCLA, Los Angeles, CA; Duke Clinical Research Institute (HX, XZ, BL), Durham, NC; Knight Cardiovascular Institute (JC), Oregon Health and Sciences University; and Department of Neurology (LHS), Massachusetts General Hospital.
University of Chicago · USUniversity of Cincinnati · USOregon Health & Science University · USUniversity of Calgary · CAUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNationwide data on patients with cryptogenic stroke (CS) are lacking. We evaluated patient and hospital characteristics, in-hospital treatments, and discharge outcomes among patients with CS compared with other subtypes in the Get With The Guidelines (GWTG)-Stroke registry.

methodsWe identified patients with ischemic stroke (IS) admitted to GWTG-Stroke participating hospitals between January 1, 2016, and September 30, 2017, with documented National Institutes of Health Stroke Scale (NIHSS) scale and stroke etiology (cardioembolic [CE], large artery atherosclerosis [LAA], small vessel occlusion [SVO], other determined etiology [OTH], or CS). Using multivariable logistic regression, we compared hospital treatments and discharge outcomes by subtype, adjusted for patient and hospital characteristics.

resultsAmong 316,623 patients from 1,687 hospitals, there were 63,301 (20.0%) patients with CS. In multivariable analysis, patients with CS received IV thrombolysis more often than other subtypes and had lower mortality than CE, LAA, and OTH but higher mortality than SVO. They were more likely to be discharged home than all other subtypes and be independent at discharge than LAA, OTH, or SVO.

conclusionsIn a large contemporary nationwide registry, CS accounted for 20% of ISs among patients with a documented stroke etiology. Patients with CS had a distinct profile of treatments and outcomes relative to other subtypes. Improved subtype documentation and further research into CS are warranted to improve care and outcomes for patients with stroke.

Identifiers

PMID33299667
PMCPMC7717635
OpenAlexW2977861926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.